The 64th Annual Meeting of ASH came to an end on December 14, 2022, Beijing time. At this meeting, Precision Biotech  disclosed the latest clinical progress of its self-developed CAR-T and universal CAR-T product candidate. The latest clinical progress of CAR-T is displayed based on the data from the Phase I clinical trial of pCAR-19B independently developed by Precision Biotech for the treatment of relapsed/refractory acute B-lymphocyte leukemia in adults. With its humanized design, the immunogenicity evaluation system of ImmEVL suitable for China population has improved the safety and effectiveness of the treatment. The latest exploration and research on general-purpose CAR-T products is the innovation of Precision Biotech in improving transduction efficiency.

An international event in the field of hematology

At present,the annual meeting of ASH is the world's largest and most comprehensive international event in hematology. Every year, the conference attracts tens of thousands of hematology experts and relevant medical professionals from more than 100 countries around the world to introduce and share the latest progress in the field of hematology.

Since the first FDA approval of CAR-T therapy in 2017, eight CAR-T drugs have been approved and marketed worldwide. This type of cell therapy has brought a great breakthrough in the treatment of malignant blood tumors. However, in the traditional autologous CAR-T therapy, individual differences lead to unstable preparation, high cost and a certain proportion of high side effects. Universal cell products can be highly uniform in process and high in stability; they can be prepared in advance, reducing the waiting period for patients; and they do not require individualized preparation to reduce costs.While developing traditional autologous CAR-T cell therapy products, Precision Biotech is also exploring different models of universal  cell therapy products, building LSTCAR® general technology platform and universal  CAR-T platform with unique general CAR-T solution for gene editing and a LAZYNK® platform with unique carrier design, efficient transduction and in vitro amplification.

Precision Biotech keeps improving the developed products and leads the innovation of next-generation products in the field. Based on autologous CAR-T products, it has the advantages of clinical research foundation, proven clinical effectiveness, and mature preparation technology. Universal cell therapy candidate such as CAR-NK products can solve the difficulties of preparing autologous products due to patient differences and high production costs. The layout of autologous and universal cell product pipelines complements each other, covering all cell types and treatment modes of immune cell therapy products. It also provides the possibility of receiving cell therapy for more malignant tumor patients.